A study presented at ACR Convergence 2025 has sparked interest among doctors and patients alike. Drugs originally made for ...

Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to ...

New research presented at ACR 2025 shows GLP-1 receptor agonists, used for diabetes and obesity, may reduce rheumatoid ...

Several factors — but not older age — increased infection risk with the use of non-TNF biologics following first-line ...

The study also presented the first external validation and use in patients with early RA of six proposed screening strategies ...

The new biotech Elevara plans to initiate Phase II testing of its lead candidate ELV001 as an add-on treatment for rheumatoid ...

Electra Therapeutics has garnered the funds it needs to complete a pivotal trial of its lead drug, angling to become the ...

A study presented at ACR Convergence 2025 suggests that GLP 1 receptor agonists reduce flares and systemic inflammation in Rheumatoid Arthritis (RA) patients.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the ...

Treatment with TNF-α inhibitors may be safer than IL-6 inhibitors in terms of cardiovascular outcomes when managing patients with RA and T2D.

Long-term flare risk and remission rates did not differ between patients with well-controlled RA who tapered vs continued MTX therapy.